Departamento de Gastroenterología.
Departamento de Ginecología Oncológica.
Cir Cir. 2023;91(2):195-199. doi: 10.24875/CIRU.22000272.
The peritoneal carcinomatosis (PC) secondary to gastrointestinal or gynecological cancer has increased its incidence. It has a worse prognosis compared to other sites of metastasis. The peritoneal carcinomatosis index (PCI) establishes overall survival in patients with gastrointestinal or gynecological tumors and carcinomatosis.
To evaluate the relationship of PCI to overall survival (OS) and recurrence-free survival (RFS) in patients treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).
A descriptive, retrolective study of 80 charts of patients with CP was conducted. We included patients with colon, ovarian, appendicular, pseudomyxoma and gastric tumors with CP treated with CRS plus HIPEC. The OS and RFS were determined according to the type of adenocarcinoma and the degree of differentiation. The OS and RFS were determined in months in patients with PCI > 15 PCI as well as in patients with PCI < 15 considering the tumor of origin.
Patients with ovarian tumors and pseudomyxoma with PCI < 15 presented OS > 70 months, compared to patients with gastric tumors (4 months).
The PCI and histology are predictors of OS. Patients with ovarian tumors and PCI < 15 have higher OS, similar to pseudomyxomas. RFS was also higher in patients with PCI < 15.
继发于胃肠道或妇科癌症的腹膜癌发病率增加。与其他转移部位相比，其预后更差。腹膜癌指数（PCI）可预测胃肠道和妇科肿瘤伴腹膜转移患者的总生存率。
评估细胞减灭术（CRS）联合腹腔内热灌注化疗（HIPEC）治疗后 PCI 与总生存（OS）和无复发生存（RFS）的关系。
对 80 例 CP 患者的图表进行描述性、回顾性研究。我们纳入了接受 CRS+HIPEC 治疗的结肠、卵巢、阑尾、假性黏液瘤和胃癌伴 CP 的患者。根据腺癌类型和分化程度确定 OS 和 RFS。根据 PCI 值（>15 或<15）以及肿瘤起源，确定 PCI>15 个月和 PCI<15 个月患者的 OS 和 RFS。
与胃癌患者（4 个月）相比，卵巢肿瘤和 PCI<15 的假性黏液瘤患者的 OS>70 个月。
PCI 和组织学是 OS 的预测因素。卵巢肿瘤和 PCI<15 的患者 OS 更高，与假性黏液瘤相似。PCI<15 的患者 RFS 也更高。
